Ninety percent of human diseases are related to abnormal inflammation. WJM team has successfully developed a new monoclonal antibody that can inhibit a key inflammation protein. Animal experiments have accumulated more than ten disease modes, including a variety of solid tumors, fibrosis, degenerativecardiovascular diseases. This antibody is qualified as an orphan drug for the treatment of IPF. New coronary pneumonia has greatly increased the demand for pulmonary fibrosis treatment,has also become an important target for mergersacquisitions of global pharmaceutical companies.

The key technology of Patient Derived Tumor Spheroids (PDTS) is to create an in-vitro patient tumor microenvironmenttumor-like properties, furthermore, predict various cancer antidrug effectiveness to each patient via the high-throughputhigh-quality cell viability detectionbiomarker analysis. Therefore, this project established several technologies including extracellular matrix fabrication, bioink design, cell population identification,tumor physiological environment for the upon goal.

DBPR807 can significantly suppress tumor growth, prevent distant metastasis, reduce angiogenesis, normalize tumor microenvironment and promote cytotoxic T-cell infiltration. In various HCC models, DBPR807 itself can prolong overall survival as effectively as marketed anti-angiogenic agent sorafenib and immune checkpoint inhibitor anti-PD-1 Ab. What’s more, its combination therapy with either sorafenib or anti-PD-1 Ab can extend life expectancy even more significantly than aforementioned monotherapy.

This technology is used to reveal the immune profiling of the tumor microenvironment based on multi-color immunohistochemistry staining. Each immune cell type will be probed with different fluorophores,the density, as well as the location of each immune cell type on the tissue slides, will be disclosed using inForm software.

We have identified a series of BPR1R compounds as highly selective CSF1R inhibitors with excellent oral bioavailability. In vivo, oral administration of BPR1R compounds delayed murine colon tumor growthreversed the immunosuppressive TME with increased M1/M2 ratio. The US & PCT patent application including more than 160 novel compounds was filed in April 20, 2020. Several potential compounds are undergoing candidate assessment for further preclinical studies.